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Abstract
Background: Hepatitis C virus (HCV) infection afflicts about 170 million individuals worldwide. However, the HCV life cycle is
only partially understood because it has not been possible to infect normal human hepatocytes in culture. The current Huh-
7 systems use cloned, synthetic HCV RNA expressed in hepatocellular carcinoma cells to produce virions, but these cells
cannot be infected with naturally occurring HCV obtained from infected patients.
Methodology/Principal Findings: Here, we describe a human hepatocyte culture permissible to the direct infection with
naturally occurring HCV genotypes 1, 2, 3 and 4 in the blood of HCV-infected patients. The culture system mimics the
biology and kinetics of HCV infection in humans, and produces infectious virions that can infect naı ¨ve human hepatocytes.
Conclusions/Significance: This culture system should complement the existing systems, and may facilitate the
understanding of the HCV life cycle, its effects in the natural host cell, the hepatocyte, as well as the development of
novel therapeutics and vaccines.
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Introduction
An estimated 170 million individuals have chronic hepatitis C
virus (HCV) infection worldwide [1]. About 70% of infected
individuals develop a chronic infection; for some, this includes
fibrosis, cirrhosis, and hepatocellular carcinoma [2,3]. Approxi-
mately, 10,000 deaths due to cirrhosis and several thousand more
deaths due to hepatocellular carcinoma are attributed to HCV
infection in the United States each year [4]. Unfortunately, there is
no vaccine available and the current treatment for HCV infection,
PEG-interferon-a in combination with ribavirin, achieves sus-
tained responses only in ,50% of treated patients [5].
The mechanisms responsible for the HCV life cycle in the liver
of infected individuals are only partially understood because it has
not been possible to infect normal human hepatocytes in culture
with naturally occurring HCV obtained from HCV-infected
patients [6], and because HCV is known to infect only humans
and chimpanzees [4].
Recently, Lindenbach, Zhong , Wakita , Yi , Murakami and
their coworkers [7–11], were able to replicate synthetic HCV
RNA in hepatocellular carcinoma Huh-7-derived cells with the
efficient production of HCV virions that were infectious to
cultured Huh-7-derived cells [7–11] chimpanzees [9,12] , and
mice containing human liver grafts [12]. Importantly, virus
recovered from these animals was highly infectious in cell culture
[12]. Also, Aly and coworkers have developed a human hepatocyte
cell line immortalized with human papilloma virus (HPV) 18/
E6E7 susceptible to HCV infection [13]. The cell line’s
susceptibility to HCV infection was further increased by inhibiting
the interferon regulatory factor-7 (IRF-7) [13].
The current Huh-7-derived HCV virions system uses non-
naturally occurring, cloned HCV genotype 2a strain (JFH-1) [7],
cloned HCV genotype 1a ( H77-S) containing five adaptive
mutations [10] , or cloned HCV genotype 1b [11]. Limitations of
this method are the use of cloned HCV, and the failure to infect
these cells with naturally occurring HCV obtained from infected
patients [14]
Further, hepatocellular carcinoma cell lines depart from normal
human hepatocytes since they have abnormal proliferation,
deregulated gene expression, dysfunctional mitochondria, and
aberrant signaling and endocytosis pathways [15–20]. Relevant
abnormalities of the Huh-7-derived cell lines include an absence of
caveolin-1 and caveolin-2 [17], a mutated p53 (Y220C) [21],
overexpression of the pituitary tumor transforming gene (PTTG)
[22],cellcycle-independentexpressionofhumantelomerasereverse
transcriptase (hTERT) [23], higher expression of glucose metabo-
lism enzymes (glucose-6-phosphate 1-dehydrogenase and isocitrate
dehydrogenase) and of a mitochondrial protein (dicarboxylate
carrier) [24] . In addition, Huh-7 cells expressed the highest level of
a-fetoprotein, a marker for hepatocellular carcinoma and de-
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[24]. Although the HPV-18/E6E7 immortalized human hepato-
cytes can be infected with serum-derived HCV, albeit at lower
levels, it also over expresses hTERT [13], and like Huh-7-derived
cells, its proliferation behavior should be that of tumor cells [24].
Consequently, any perturbation of these normal hepatocyte
functions by the HCV infection cannot be studied completely
and/or accurately in the Huh-7-derived HCV virions system or the
HPV-18/E6E7 immortalized human hepatocytes [14].
Valuable studies by Fournier, Molina and their coworkers have
allowed the culture of HCV in primary human hepatocytes [25–
27]. However, this culture hepatocyte system had limited
efficiency since less than 15% of the sera were infectious [25],
the amplification was less than 1 log10 [25,26], the infection
declined after 8 days , it was detectable only in the cell layers until
day-14, and there was no evidence of the production of infectious
virions [25–27] Thus, there are still no effective means for directly
culturing and significantly amplifying HCV from typical clinical
specimens using differentiated normal human hepatocytes [4].
Here, we report the development of a normal human hepatocyte
culture system permissible to the infection with, and physiologi-
cally significant amplification of, naturally occurring HCV.
Results
Infection of Primary Human Hepatocyte Cultures with
Naturally Occurring HCV
We used primary human hepatocytes that were isolated from
normal liver explants, and sera from chronically HCV-infected
patients with high viral titers, in an attempt to infect human
hepatocytes. Some stringent conditions of the culture system were
required for achieving a successful HCV infection of human
hepatocytes (see Methods).
Using these conditions, we attained a robust infection of human
hepatocyte cultures with naturally occurring HCV obtained from
33 of 36 consecutive HCV-infected patients, with 3 of 36 failures.
HCV infection was achieved in human hepatocyte cultures from
29 different liver donors. Cells were cultured at a high density on a
three-dimensional specific collagen type 1 matrix, and in a defined
medium without serum, and with liver sinusoidal cells, conditions
that allowed hepatocytes to become highly differentiated,
recapitulating the physiology of hepatocytes within the liver as
we reported previously [14,18,28]. On day-5, the human
hepatocyte culture system was composed of approximately 95%
hepatocytes, and 5% liver sinusoidal endothelial cells and hepatic
stellate cells, mimicking the hepatocyte organoid rodent cell
culture [29]. As determined by RT-PCR , these uninfected human
hepatocyte cultures expressed glial fibrillary acidic protein (GFAP),
CD-34, complement receptor-1 (CR1), hepatocyte growth factor
(HGF) and CD-68, genes also expressed in a normal liver by
hepatic stellate cells, endothelial cells, smooth muscle cells and
macrophages [19,30–33]. The RNA values were compared to
those of a normal uninfected human liver (Figure 1A). This may
be relevant since these stellate cells and sinusoidal endothelial cells
produce HGF, a critical factor for hepatocyte differentiation and
survival [31,34–35]. In turn, HGF activates the CCAAT/
enhancer binding protein- b (C/EBPb) [36] which upon
phosphorylation induces hepatocyte survival [28].
Naturally occurring HCV genotype 1 infection of human
hepatocyte cultures developed rapidly, as reflected by the intense
expression of HCV E-2, core and NS3 proteins in the cell layers,
after a 24-hr exposure, on laser scanning confocal microscopy using
specific antibodies [37] (Figure 1B and 1C). The HCV E-2 and
core proteins were co-localized in the perinuclear region of the
human hepatocytes infected with HCV genotype 1, while
uninfected control hepatocytes had only background fluores-
cence (Figure 1B). This perinuclear localization resembles the
previously reported HCV virions in the liver of HCV-infected
patients and chimpanzees [38–39]. In the HCV-infected
hepatocytes, the TO-PRO3 stain for nucleic acids, detected
hepatocyte nuclear DNA but also nucleic acids in the cytoplasm
of hepatocytes in a ‘salt and pepper’ pattern (Figure 1B).
Because this nucleic acid is co-localized with HCV proteins,
such as E-2 and core, and it is not expressed either in
uninfected control human hepatocyte cultures (Figure 1B),o r
in the same hepatocytes cultured in the presence of control
human serum, it is not spurious patients’ RNA or DNA
contaminating the cells or the inoculum, and most likely
represents HCV RNA. Moreover, the scanning confocal laser
microscopy technique eliminates the possibility of detecting
nucleic acids attached to the hepatocyte cell membrane. Further
the expression of HCV E-2 and core as well as the cytoplasm
nucleic acid was also observed in the liver of HCV-infected
patients, but not in control livers (Figure 1B). Another HCV
protein, NS3, was also detected in the human hepatocyte
cultures infected with HCV genotype 1 after a 24-hr exposure,
but not in uninfected control human hepatocyte cultures
(Figure 1C). The expression of HCV NS3 was also observed
in the liver of HCV-infected patients, but not in control livers
(Figure 1C). A similar expression of HCV E-2, core and NS3
proteins was also observed in human hepatocyte cultures after a
24-hr infection with HCV genotypes 2 or 3 (Figure S1).
HCV Amplification in the Human Hepatocyte Culture
System
Under the conditions that we described, human hepatocyte
cultures remained infected for at least 3 weeks. The amplification of
HCV genotype 1 infection was analyzed by immunopurifying HCV
virions from the medium through HCV E-2 affinity chromatogra-
phy. The HCV amplification was robust judging by the increased
HCV core and E-2 in the medium from time zero (inoculum) to 72
hr (Figure 2A). Control samples from uninfected hepatocytes
lacked detectable HCV core or E-2 proteins.
We evaluated the presence of full-length HCV RNA in the
human hepatocyte culture by Northern blot, using specific probes
cloned from each donor patient’s HCV RNA. The large viral load
required for this cloning was obtained from large phlebotomies
needed for the treatment of iron overload in patients with Genetic
Hemochromatosis that also had HCV infection genotypes 1, 2 and
3.TheHCVRNAwasofthe expected size,and itwas detected only
in HCV-infected human hepatocyte cultures, but not in uninfected
human hepatocyte cultures (Figure 2B). We also assessed the
infection-replication cascade by determining HCV viral particles in
the hepatocyte cultures from time zero to 72 hr and from zero to
week-3. As detected by quantitative RT-PCR, using modified
standard clinical COBAS amplification primers, the HCV RNA
increasedexponentiallyupto5 log10,72hraftera HCV genotype 1
infection (P,0.01) (Figure 2C) , and remained at a steady-state
between 5 log10 and 6 log10 for up to week-3 for HCV genotypes 1,
3a n d4( P,0.001) (Figure 2D). Using the same assay protocol, the
HCV RNA, corrected by total RNA, was comparable in human
hepatocyte cultures after day-2 and in the liver of HCV-infected
patients (Figure 2C and 2D). These data further support the
validity of the human hepatocyte culture system to study HCV
infection. Although the half-life of HCV virions is less than 5 hours
in HCV-infected patients [40], it remains to be determined whether
the half–life of HCV virions in the hepatocyte culture is similar in
the absence of a fully competent immune system.
Infection of Hepatitis C Virus
PLoS ONE | www.plosone.org 2 July 2008 | Volume 3 | Issue 7 | e2660Figure 1. HCV Infection Genotype 1 of the Human Hepatocyte Culture System. A. Day-5 human hepatocyte cultures were assessed by RT-
PCR for GFAP, CD-34, CR-1, HGF and CD-68. Values were normalized to control human liver and expressed as fold changes from baseline. GFAP and
CD-68 were increased compared to control human liver (P ,0.05). B. Day-5, primary human hepatocytes infected with HCV genotype 1 (inoculum:
11,200 HCV virions) and control cells, as well as liver from HCV-infected patients or control liver were processed as described in Materials and
methods. Scanning confocal laser microscopy was performed for nucleic acids (TO-PRO-3), HCV E-2 and HCV core. Twenty-four hour infected
hepatocytes expressed HCV E-2 and core proteins. Control hepatocytes had only background fluorescence for HCV E-2 and core proteins (upper
panels). HCV-infected liver expressed also HCV E-2 and core proteins. Control liver hepatocytes had only background fluorescence for HCV E-2 and
core proteins (lower panels). Co-localization of HCV E-2 (red) and HCV core (green) is shown in yellow (merge), while co-localization of nucleic
acids (blue), HCV E-2 (red) and HCV core (green) is shown in white (merge) in both HCV-infected human hepatocyte cultures and liver . The control
hepatocytes had the same amount of control human serum. C. HCV NS3 was determined by scanning confocal laser microscopy in the samples
described in (B). Twenty-four hour infected hepatocytes expressed HCV NS3 protein. Control hepatocytes had only background fluorescence for HCV
NS3 protein. Co-localization of HCV NS3 (green) is shown in yellow (merge) in HCV-infected human hepatocyte cultures (upper panels) and HCV-
infected human liver (lower panels). The control hepatocytes had the same amount of control human serum. Representative results from
quadruplicate samples of ten independent experiments with human hepatocytes cultures and seven human liver samples (4 patients with chronic
hepatitis C viral infection and severe liver fibrosis and 3 control livers) are shown.
doi:10.1371/journal.pone.0002660.g001
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proteins E-2, and core up to 21 days in human hepatocytes
infected with HCV genotype 1 (P,0.05) (Figure 3A), obtained
from a patient chronically infected with HCV. Also, we detected a
rapid amplification of HCV genotypes 1, 2, 3 and 4, twenty-four
hours after HCV infection judging by E-2 immunopurification
(Figure 3B). Uninfected, control human hepatocyte cultures did
not express either HCV E-2 or core proteins (Figure 3A and
3B). In addition, expression of HCV NS3 and NS5a was also
amplified in human hepatocytes infected with HCV genotypes 1, 2
and 3 (Figure 3C and 3D). Collectively, these data indicate a
robust HCV infection of the normal human hepatocyte culture
system for up to 3 weeks (Figures 2 and 3).
The HCV infection of the normal human hepatocyte system
was consistent. Sera from 33 of 36 HCV-infected patients
successfully infected the normal human hepatocyte culture system.
Figure 2. HCV RNA Amplification in the Human Hepatocyte Culture System. Day-5 primary human hepatocytes were infected with HCV
genotype 1 (56,000 HCV virions); genotype 2 (68,000 HCV virions); genotype 3 (22,400 HCV virions); or genotype 4 (41,800 HCV virions) for up to
week-3 as described in Materials and methods. A. HCV genotype 1 virions in the media were purified by affinity chromatography. Immunoblotting
for HCV E-2 and core proteins was done in HCV lysates at time zero (inoculum) and at 72 hr. Immunoblots were quantified on a Kodak 4000 Imaging
Station and software as described in Materials and methods. Samples are core at zero and 72 hr ; E-2 at zero and at 72 hr ( P,0.05 for E-2 and core) .
B. HCV RNA was determined by Northern blot in primary human hepatocytes control or infected with HCV genotype 1 ; genotype 2 and genotype 3
as described in (A). HCV RNA of the expected size is expressed in HCV-infected human hepatocyte cultures, but not in control cells. Results from
duplicate samples of three independent experiments are shown. C. HCV RNA was quantified by RT-QPCR in triplicate samples from primary human
hepatocytes infected with HCV genotype 1 at 7, 12, 24, 48, and 72 hr, as well as from the livers from two HCV-infected patients (HCV RNA ,6 log10).
The HCV RNA increased to ,3 log10 at 48 hr and to ,5 log10 at 72 hr (P,0.01). D. HCV RNA was quantified by RT-QPCR in primary human
hepatocytes infected with HCV genotype 1 (closed bars); genotype 3 (open bars) and genotype 4 (hatched bars) at day-2, week-2 and week-3,
and from livers of two HCV-infected patients (HCV RNA ,5 log10). The HCV RNA increased to ,5 log10 at day-2 and remained at that level at week-2
and week-3 (P ,0.001). Results from quadruplicate samples of six independent experiments are shown.
doi:10.1371/journal.pone.0002660.g002
Infection of Hepatitis C Virus
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infection of the human hepatocytes in 3 cases. None of the sera
from the uninfected control subjects induced any false positive
parameter of HCV infection in the normal human hepatocyte
system. The subject population included individuals with chronic
HCV infection, viral load .700,000 IU/ml and genotypes 1 (n:
21), 2 (n: 5), 3 (n: 6), or 4 (n: 4), but negative for Hepatitis A and B,
and HIV. Control sera were obtained from 3 subjects negative for
Hepatitis A, B and C, and HIV.
HCV-Infection of Normal Human Hepatocytes is
Dependent on CD-81 and HCV E-2
The mechanisms of hepatitis C viral entry have been extensively
investigated. It is known that E-2 dimerizes with E-1, and
associates with the cellular CD-81 and the SR-BI receptors, which
has proven to be critical for entry of HCV virions [41,42]. It has
also been documented that HCV entry mechanisms involve
cholesterol content of the plasma membrane [42–45]. Therefore,
we assessed whether these mechanisms also are required for HCV
Figure 3. HCV E-2, Core and NS3 Amplification in the Human Hepatocyte Culture System. Day-5 primary human hepatocytes were
infected with HCV genotype 1 (56,000 HCV virions); genotype 2 (68,000 HCV virions); genotype 3 (22,400 HCV virions); or genotype 4 (41,800 HCV
virions) for up to week-3 as described in Materials and methods. A. HCV E-2 and core were detected by immunoblotting from human hepatocytes
cell layers. E-2 and core were expressed in HCV genotype 1-infected hepatocyte cultures for day 1 , day 3 , day 6 , day 10 , day 13 , day 15 , and day 21,
compared to control time-zero HCV infection . b-Actin was used as a control for immunoprecipitation. E-2 and core immunoblots shown were
quantified on a Kodak 4000 Imaging Station and software; P ,0.05 for expression starting on 24 hr when compared to control samples. B. HCV E-2
was detected by immunoblotting from HCV-infected human hepatocytes cell layers. E-2 was expressed in human hepatocytes infected with HCV
genotypes 1, 2, 3 and 4 for 24 hr, compared to control at zero time. b-Actin was used as a control for immunoprecipitation. E-2 immunoblots were
quantified on a Kodak 4000 Imaging Station and software. The HCV E-2 increased to ,4 log10 at 24 hr for HCV genotypes 1, 2, 3 and 4 (P ,0.01).
Representative results from triplicate samples of five independent experiments are shown. C. HCV NS3 and NS5a were detected by immunoblotting
from HCV-infected human hepatocytes cell layers. NS3 and NS5a were expressed in human hepatocytes infected with HCV genotypes 1, 2, and 3 at
day-10, compared to control at zero time. b-Actin was used as a control for immunoprecipitation. NS3 and NS5a immunoblots were quantified on a
Kodak 4000 Imaging Station and software. The HCV NS3 and NS5a increased to ,4 log10 for HCV genotypes 1, 2, and 3 (P ,0.01). Representative
results from triplicate samples of three independent experiments are shown.
doi:10.1371/journal.pone.0002660.g003
Infection of Hepatitis C Virus
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HCV infection of the human hepatocyte culture system with
genotype 1 can be blocked with antibodies specific to CD-81 or
HCV E-2 (Figure 4A), or by cholesterol depletion with MbCD
(Figure 4B) (P,0.05 for all treatments), as reported previously
for Huh-7 cells [7] [42,46]. Further, the HCV E-2 antibodies also
inhibited HCV infection with genotypes 2, 3 and 4 (P,0.05 for all
treatments). Control human IgG did not affect HCV infection
(Figure S2).
As expected, the effects of MbCD were rescued by reconstitut-
ing cholesterol (Figure 4B), as reported previously for Huh-7
cells [42]. In addition, HCV replication was inhibited by methyl
cytidine (P,0.05) (Figure 4C), as reported previously for Huh-7
cells [47]. The effects of these interventions were determined by
measuring HCV RNA. The significant effects of these blockers
and inhibitors on HCV infection suggest that the human
hepatocyte culture system is physiologically relevant to the study
of HCV infection, as previously documented for the Huh-7 cell
system.
The HCV Infection Modulates Interferon-Related Genes in
the Human Hepatocyte Culture System
Because IFN induction and IFN signaling are important
responses to HCV infection [48], we investigated these pathways
in the hepatocyte culture system before and after HCV infection.
Using a microarray assay to assess expression of 83 interferon-
related genes in the human hepatocyte culture system, 72-hr after
infection with HCV genotypes 1, 2 or 3, we found a substantially
altered gene expression, when compared to uninfected, control
human hepatocytes (Figure 5A and Table S1). Consistent
increases were observed after a 72-hr HCV infection for the
following genes : i] IL-15 ( # 48); ii] IFN-R 1 (# 33) ; iii] IRF-3 (#
69); iv] IRF-7 ( # 73) ; v] IRF-8 ( # 74) ; vi] IRF-2 binding protein
1(# 67) ; vii] IRF-2 binding protein 2 ( # 68); viii] IRF-2 (# 66) ;
ix] Adenosine deaminase (# 1) ; and x] Oligoadenylate synthase
(# 79) (Table S1 ). In contrast, consistent decreases were
observed after a 72-hr HCV infection for the following genes : i]
IFN-induced Protein 44-like ( # 17); ii] IFN-a 2( # 27) ; iii] IRF-a
4( # 29); iv] IRF-a 14 ( # 26) ; v] IRF-a 8(# 32) ; vi] IRF-a 6(#
31); vii] IRF-a 1(# 25); viii] IRF-related Development Regulator
1( # 41) ; ix] IL-21R (# 50) ; x] IL-22R a ( # 51); xi] IL-28A ( #
52); and xii] Chemokine ligand 10 ( # 6) (Table S1 ).
Treatment of human hepatocytes with interferon 18hr before
HCV infection, inhibited HCV amplification as measured by RT-
PCR for HCV RNA 72 hr later (P,0.05) (Figure 5B).
Treatment of human hepatocytes with interferon for 72 hr , 24-
hr after the HCV infection with genotypes 1, 2, 3 or 4, inhibited
HCV amplification by ,1 log10 (from ,7 log10 ), when compared
to untreated HCV-infected human hepatocytes, as measured by
RT-PCR for HCV RNA (P,0.05) (Figure 5C). These results
further emphasize the physiological relevance of the HCV-infected
hepatocyte culture system.
The Normal Human Hepatocyte Culture System Produces
Infectious HCV
HCV virions produced by the primary HCV-infected human
hepatocyte cultures were infectious to naı ¨ve normal human
Figure 4. HCV-Infection with Genotype 1 of Normal Human
Hepatocytes is Dependent on HCV E-2 and CD-81. Day-5 primary
human hepatocytes were infected with HCV genotype 1 (56,000 HCV
virions) as described in Materials and methods. HCV RNA replication
was determined at 72 hr after infection. A. Human hepatocyte cultures
were treated prior to HCV infection without or with antibodies specific
to CD-81 and HCV E-2 as described in Materials and methods.
Antibodies against CD-81 and HCV E-2 decreased HCV RNA (P,0.05).
The control hepatocytes had the same amount of control human IgG.
B. Human hepatocyte cultures were treated prior to HCV infection
without or with MbCD, MbCD and cholesterol, or cholesterol control as
described in Materials and methods. Cholesterol depletion with MbCD
decreased HCV RNA (P,0.05), which was partially rescued by the
addition of cholesterol (NS). Treatment with cholesterol alone had no
effect on HCV RNA (NS). C. Human hepatocyte cultures were treated
prior to and during HCV infection without or with methyl cytidine as
described in Materials and methods. Treatment with methyl cytidine
decreased HCV RNA (P,0.05). Results from triplicate samples are
shown.
doi:10.1371/journal.pone.0002660.g004
Infection of Hepatitis C Virus
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virions from HCV-infected patients (into the ‘primary’ culture)
and HCV virions produced by normal human hepatocyte cultures
(into the ‘secondary’ culture) was comparable (Figure 6). This
was judged by the viral amplification as determined by
immunopurification of HCV E-2, and quantified either on a
Kodak 4000 Imaging Station and software as described [31]
(P,0.05) (Figure 6, upper panel), or by the incorporation of
[
35S]-methionine into the newly synthesized HCV E-2 protein in
the secondary infection (P,0.01) (Figure 6, lower panel).
Because it has been suggested that infectious HCV virions and
infectious Huh-7 produced particles represent a subset banding at
a density slightly lower than that of most virions and particles [49–
51], we isolated HCV virions by isopycnic ultracentrifugation
through an iodixanol gradient as described by Yi and coworkers
[51]. As described in Table 1 for HCV genotype 1, the density of
the naturally occurring HCV in the serum of the patient fluctuated
between 0.979 g/cm
3 and 1.258 g/cm
3. Similarly, the densities of
the HCV virions in primary and secondary human hepatocyte
infection fluctuated between 0.987 g/cm
3 and 1.298 g/cm
3, and
0.990 g/cm
3 and 1.259 g/cm
3, respectively (Table 1). The
highly infectious HCV virions and particles are believed to
concentrate in those with densities below 1.09 g/cm
3 [50] [51]. In
our analysis for HCV genotype 1, approximately 82% of the
patient’s HCV, 86% of the HCV in the primary infection, and
90% of the HCV in the secondary infection corresponded to those
densities, suggesting that they were infectious (Table 1). The
higher HCV densities may correspond to other forms of HCV
virions. For example, the nucleocapsid of HCV, isolated by
different detergent treatments, was estimated to have a buoyant
density of 1.25 g/ml in sucrose [49] , and some clinical HCV
samples have densities .1.13 g/ml [49–50]
A similar pattern was observed for HCV genotypes 2 and 3.
The percentage of HCV virions that concentrate in densities
below 1.09 g/cm
3 , were approximately 82% and 80% for HCV
genotype 2, and 85% and 87% for HCV genotype 3 , in the
primary infection and in the secondary human hepatocyte culture
system , respectively (Table S2)
To our knowledge, this is the first report of a physiologically
significant amplification of HCV infection (up to 7 log10 ) with
Figure 5. The HCV Infection Modulates Interferon-Related Genes in the Human Hepatocyte Culture System. A. Day-5 primary human
hepatocytes were infected with HCV genotype 1 (28,900 HCV virions), genotype 2 (36,200 HCV virions ), or genotype 3 ( 30,800 HCV virions ) as
described in Materials and methods. A panel of 83 interferon-related genes was evaluated by RT-QPCR; 22 of these genes were significantly altered
(P,0.05 for all genes) compared to control uninfected human hepatocyte cultures . Values for genotypes 1, 2 and 3 are depicted in black, blue and
red, respectively. B. Day-5 human hepatocyte cultures were treated 18 hr prior to and for 72 hr during the HCV infection without or with IFN-a as
described in Materials and methods. Treatment with IFN-a decreased HCV RNA (P,0.05) . C. Day-5 human hepatocyte cultures were treated for 72 hr,
24 hr after the HCV infection with genotypes 1, 2, 3 or 4 without or with IFN-a as described in Materials and methods. Treatment with IFN-a
decreased HCV RNA (P,0.05 for all genotypes).
doi:10.1371/journal.pone.0002660.g005
Infection of Hepatitis C Virus
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hepatocyte culture system, suggesting that research with this
physiological system may complement that available with the
current replicon systems [7–9].
Discussion
The differentiated normal human hepatocyte cell culture
described here is a system suitable for investigations of the HCV
life cycle, of naturally occurring genotypes 1, 2, 3 and 4 obtained
from HCV-infected patients. The infection of normal human
hepatocytes was robust for at least 3 weeks and consistent, since
normal human hepatocytes from 29 different liver donors were
infectedwithserafromatleastoneof33HCV-infectedpatients.The
HCV amplification achieved in these experiments was up to 7 log10
and comparable to that detected in HCV-infected human livers.
HCV infection was validated by seven different approaches: i)
time-dependent amplification of newly synthesized HCV RNA (as
detected by Northern blot and RT-QPCR ); ii) time-dependent
amplification of HCV proteins in cell layer and media (as detected
by immunopurification); iii) production of HCV virions that were
infectious to naı ¨ve human hepatocyte cultures ( as detected by RT-
PCR for HCV RNA; HCV E-2 de novo synthesis with [
35S]-
methionine; and E-2 amplification by immunopurification); iv)
production of HCV virions with densities below 1.09 g/cm
3,
consistent with highly infectious virions [50–51]; v] blockade of
HCV infection with antibodies specific to HCV E-2 and CD-81,
or cholesterol depletion with MbCD [40–42]; vi) IFN-a and
methyl cytidine , inhibitors of HCV replication [7,47] prevented
HCV amplification; and vii] induction of a physiological response
of interferon-related genes to the HCV infection.
Valuable studies by Fournier, Molina and their coworkers have
allowed the culture of HCV in primary human hepatocytes [25–
27]. However, this culture hepatocyte system had limited efficiency
since less than 15% of the sera were infectious [25], the
amplification was about 1 log10 [25–26], the infection declined
after 8 days , it was detectable only in the cell layers until day-14,
and there was no evidence of the production of infectious virions
[25–27] . The main apparent differences between the system
reported by Fournier, Molina and co-workers [25–27], and our
system are the following: i] our cellular viability was higher (95% vs.
70–90%) and more stringent (apoptosis and ALT assessment); ii]
our cell attachment was induced with higher concentration of fetal
calf serum ( 20% vs. 5%) for longer (up to 18 hr vs. 4 hr); iii] in our
system, the matrix was rat-tail collagen; iv ] in our system, the
collagen matrix was freshly prepared within 24hr of hepatocyte
plating, at a concentration of 50 mg/ml or greater; v] in our system,
the culture plates were coated with polylysine; and vi] our density
plating was higher (1.8 million vs. 0.14 million/60 cm
2 plate) [25] .
The current Huh-7-derived HCV virions system is simple, but
allows replication of only synthetic RNA expressed from selected
cloned genomic or subgenomic HCV. Although naı ¨ve Huh-7-
derived cells can be infected with virions produced by Huh-7 cells
transfected with HCV RNA from specific clones, this system
cannot be infected with naturally occurring HCV, indicating
another major departure of the Huh-7 system from the biology of
human HCV infection. In contrast, the normal human hepatocyte
system is permissible to infection with naturally occurring HCV
genotypes from most patients tested to date, reproducing the high
susceptibility of humans to HCV infection of all genotypes [4].
In addition blockers of cell entry and inhibitors of HCV
replication [7,41,42,47] prevented HCV replication in the human
hepatocyte culture system.Collectively,these resultssuggest that the
normal human hepatocyte culture system mimics some relevant
aspects of the infection of hepatocytes by HCV in patients.
Therefore, the normal human hepatocyte system may allow high
throughput testing of patients’ HCV susceptibility to novel drugs,
and identification of putative molecular mechanisms within
hepatocytes that may explain patients’ genetic or acquired
resistance to a treatment. For example, hepatocytes cell cultures
and HCV could be from donors with various ethnic and genetic
backgrounds such as those refractory to HCV treatment (e.g.,
African Americans). In addition, this hepatocyte system may
facilitate early identification of unanticipated cellular targets of
Figure 6. The Human Hepatocyte Culture System Produces
Infectious HCV. Day-5 primary human hepatocytes (1.8 million cells/
60 cm
2) were infected with HCV genotype 1 (56,000 HCV virions);
genotype 2 (68,000 HCV virions); or genotype 3 (22,400 HCV virions) for
72 hr as described in Materials and methods. Upper panel. HCV E-2
was detected by immunopurification and immunoblotting from cell
layers of naı ¨ve primary human hepatocytes infected with HCV
genotypes 1, 2 or 3 for 72-hr (lanes 5–7) produced by human
hepatocytes infected with HCV genotypes 1, 2 or 3 for 72-hr (lanes 2–
4) as described in Materials and methods. Control uninfected
hepatocytes are shown in lane 1. Middle panel. E-2 immunoblots
were quantified on a Kodak 4000 Imaging Station and software; P ,0.05
for E-2 expression for primary (lanes 2–4) and secondary (lanes 5–7)
infections when compared to control samples (lane 1). Results from
triplicate samples of two independent experiments are shown. Lower
panel. [
35S]-methionine labeling of HCV E-2 in the secondary infection
of human hepatocytes infected with HCV genotypes 1, 2 or 3 (lanes 5–
7) produced by the human hepatocyte primary infection. HCV infection
was quantified by determining the radioactivity of immunopurified HCV
E-2 (P,0.01); background radioactivity was negligible. b-Actin was used
as a control for immunoprecipitation. Results from triplicate samples of
three independent experiments are shown.
doi:10.1371/journal.pone.0002660.g006
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preventing drug-induced liver injury in clinical trials [52]. Further,
clinically relevant conditions for HCV infection, such as insulin
resistance, fatty liver and iron overload [53–54] can be mimicked in
these cultures (MB, unpublished observations). In contrast, these
physiologically important culture conditions are unlikely to be
mimicked in the Huh-7 hepatocellular carcinoma system.
In addition, the human hepatocyte culture system had a
physiological response to the HCV infection since many of the 83
interferon-related genes were substantially affected, as reported in
the livers of HCV-infected patients [55]. These findings suggest
that the human hepatocyte system for HCV infection may
contribute to the understanding of the relationship between
HCV viral proteins and cellular anti-viral mechanisms, including
IFN induction and IFN signaling [48].
The Huh-7 system is capable of generating infectious HCV
virions; however, the repertoire is limited with only several HCV
chimeric clones available at present [7]. Both the Huh-7 and
human hepatocyte systems have comparable high-level replication
for a few weeks. While only ,2% of the replicon Huh-7-derived
cells were NS5-positive on day-5, reaching 100% infection on day-
24 [8], about 95% of the human hepatocytes were infected with
naturally occurring HCV at 24 hr, as indicated by the expression
of HCV E-2 and core by confocal scanning laser microscopy.
Thus, the human hepatocyte culture system is infected with
naturally occurring HCV, at least as rapidly as the Huh-7 cells,
mimicking the kinetics of HCV infection in humans. In support of
our human hepatocyte HCV infection system, primary hepato-
cytes from the tree shrew Tupaia belangeri, specie susceptible to
infection by hepatitis viruses, were also susceptible to HCV
infection with sera from HCV-infected patients [56].
Current research uses readily available Huh7-derived hepato-
cellular carcinoma cells, while the HPV-18/E6E7-human hepa-
tocyte system uses immortalized cells. However, unlike the normal
human hepatocytes described in this study, the Huh-7- derived
cells are de-differentiated and characterized by abnormal
proliferation, deregulated gene expression, dysfunctional mito-
chondria and aberrant endocytosis and signaling pathways [15–
18,20–24]. Similarly, the HPV-18/E6E7 immortalized human
hepatocytes have an ectopic expression of hTERT [13], which
results in aberrant proliferation and could be tumorigenic [24]. It
is unknown whether the HPV-18/E6E7 immortalized human
hepatocytes are producing infectious HCV virions.
The HCV infection in patients induces proliferation of HCV-
infected hepatocytes as determined in liver biopsies by nuclear
staining of PCNA (M Buck, unpublished observations). In contrast,
the HCV infection system occurs in Huh-7 cancer cells with a high
baseline proliferation rate, and does not affect the degree of cell
proliferation (M Buck, unpublished observations). Therefore, the
differentiated, HCV-infected normal human hepatocyte culture
system may help identifying the effects of HCV viral proteins on
hepatocyte proliferation and carcinogenesis, signaling pathways,
endocytosis, gene expression, and mitochondrial function [14].
The HCV infection of the hepatocyte culture system with
naturally occurring HCV virions mimics the biology and kinetics
of HCV infection in humans, and produces infectious virions that
can infect naı ¨ve human hepatocytes. We also determined that
most of the HCV virions for genotypes 1, 2, and 3 produced by the
primary and secondary human hepatocyte cultures, have a density
consistent with those of infectious HCV virions, as proposed
previously by Hijikata, Yi and their coworkers [50–51]. It remains
to be determined by future investigations whether these HCV
virions are infectious to chimpanzees and to mice containing
human liver grafts as it has been documented with the Huh-7
generated virions [9,12].
Clinical Implications
This study suggests that the human hepatocyte culture system
described here will complement the Huh-7 virions system in
understanding the HCV life cycle, it effects on the hepatocyte, the
natural host cell, as well as the possible development of novel
therapeutics and vaccines. The human hepatocyte culture system
may facilitate studies of the role of insulin resistance and fatty liver
on HCV infection since these conditions can be mimicked in the
human hepatocytes. Similarly, the mechanisms by which African
Americans are refractory to HCV treatment could possibly be
analyzed by infecting human hepatocytes from different ethnic
backgrounds and studying their response to treatments.
Materials and Methods
The projects involving human subjects were reviewed and
approved by the University of California, San Diego’s Human
Protection Research Committee.
Human Primary Hepatocyte Cultures
We obtained hepatocytes (from Tissue Transformation Tech-
nologies [Edison, NJ], CellzDirect [Durham, NC], Invitrotechnol-
ogies [Baltimore, MD], and BD Biosciences [Woburn, MA]) from
anonymous organ donors without liver disease that were not
Table 1. The Normal Human Hepatocyte Culture System Produces HCV Genotype 1 with a Density of Infectious Virions.
HCV Genotype 1 (Serum) HCV Genotype 1 (Primary Infection) HCV Genotype 1 (Secondary Infection)
Density (g/cm
3) RNA (IDV) Density (g/cm
3) RNA (IDV) Density (g/cm
3) RNA (IDV)
0.979 8851833 0.987 12132120 0.990 3451200
1.031 9698598 1.012 30425472 1.003 12611840
1.049 6776352 1.034 3345300 1.015 7651520
1.067 5189958 1.052 27534276 1.076 12516160
1.258 6541992 1.298 16558080 1.259 7376960
HCV genotype 1 virions were isolated by isopycnic ultracentrifugation through an iodixanol gradient as described in Material and methods from patients’ serum , from
the human hepatocyte primary infection and from the human hepatocyte secondary infection. The densities below 1.09 g/cm
3 consistent with infectious virions,
comprised approximately 82% of the patient’s serum, 86% of the primary infection, and 90% of the secondary infection. HCV virions in each fraction were assessed by
RT-PCR for HCV RNA , as described in Material and methods.
doi:10.1371/journal.pone.0002660.t001
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reasons. These donors were negative for Hepatitis A, B and C,
CMV, HIV, HTLV K, and RPR-STS.
Hepatocyteswereisolated from an encapsulatedliver sampleby a
modified two-step perfusion technique introduced by Seglen [57].
Briefly, the dissected lobe was placed into a custom-made perfusion
apparatus and two to five hepatic vessels were cannulated with
tubing attached to a multi-channel manifold. A liver fragment (150
to 500 g) was perfused initially (recirculation technique) with
calcium-free HBSS supplemented with 0.5 mM EGTA for 20 to
30 min and then with 0.05% collagenase [Sigma] dissolved in L-15
medium (with calcium) at 37uC until the tissue was fully digested.
The digested liver was removed, immediately cooled with ice-cold
L-15 medium and the cell suspension was strained through serial
progressively smaller stainless steel sieves, with a final filtration
through 100-micron and 60-micron nylon mesh. The filtered cell
suspension was aliquoted into 250-ml tubes and centrifuged three
times at 40 g for 3 min at 4uC. After the last centrifugation, the cells
were re-suspended, in HypoThermosol-FRS [BioLife Solutions,
Inc] combined in one tube and placed on ice.
Cells were centrifuged at 700 rpm for 5 min at 4uC, the
supernatant was removed and the cells were washed with Hanks
Wash Solution (53.6 mM KCl 0.4 g/l; 4.4 mM KH2PO 0.06 g/l;
1.37 M NaCl 8 g/l; 3.4 mM Na2HPO4 0.048 g/l; 20 mL CaCl2
(2M)) three times. Cells were re-suspended in Hepatocyte Plating
Media (500 mL DMEM high glucose; 20% FBS) and plated at a
concentration of at 0.625610
6 cells/mL. We used diluted collagen
(type 1, rat tail-BD Cat. #354236) (50 mg/ml in 0.02N acetic acid)
for coating coverslips and plates in about 10ml (enough to cover
them) at room temperature for one hour. The collagen solution
was then removed and rinsed once with PBS. After the cells
attached (,18 hrs), the HPM was replaced by Hepatocyte Media
(500 mL DMEM high glucose; 30 mg L-methionine; 104 mg L-
leucine; 33.72 mg L-ornithine; 200 mL of 5mM stock dexameth-
asone; 3 mg Insulin)
Hepatocyte culturing conditions required for infection
with naturally occurring HCV
These conditions include the following: 1) the matrix was rat-tail
collagen( BD Biosciences); 2) the collagen matrix was prepared
within 24 hr of hepatocyte plating , at a concentration of 50 mg/
ml or greater; 3) the culture plates were coated with polylysine; 4)
the rinsing of the matrix was minimal; 5) the suspended
hepatocytes were allowed to attach in 20% fetal calf serum for
not more than 18 hr; 6) the hepatocyte-specific media was given
for at least 24 hr prior to the HCV infection; 7) the hepatocytes
were .85% confluent until the time of infection; 8) hepatocyte
cultures with .5% apoptosis by annexin-V assays and/or
increases .3-fold in ALT were discarded; 9) hepatocyte media
was changed every 72 hr.
Human HCV-positive Sera
Sera from 36 HCV-infected patients and 3 control subjects were
obtained at the VA San Diego Healthcare System Clinical
Laboratory. The subject population included individuals with
chronic HCV infection, viral load .200,000 IU/ml and genotypes
1( n: 21), 2 (n: 5), 3 (n: 6), or 4 (n: 4), but negative for Hepatitis A
and B, CMV and HIV. The HCV viral load was determined by
using the COBAS TaqMan HCV real-time PCR assay (Long
Beach VA Medical Center, Long Beach, CA). The dynamic range
is 25–100,000,000 IU/mL. Control sera (n: 3) were obtained from
subjects negative for Hepatitis A, B and C, CMV and HIV. In
different experiments, the primary inoculums fluctuated between
3,728 and 68,000 HCV viral particles (maximally 1.2 viral
particle/25 hepatocytes). The incubation time for the inoculum
was 1 hr.
Dependence of HCV-Infection of Normal Human
Hepatocytes on CD-81 and HCV E-2
Day-5 primary human hepatocytes were infected with HCV
genotype 1 (56,000 HCV virions) as described above. Human
hepatocyte cultures were treated with antibodies specific to HCV
E-2 (25 mg/ml) (BioDesign), CD-81 (25 mg/ml) (Santa Cruz
Biotech.) and normal human IgG (25 mg/ml) for 18 hr prior to
HCV infection), or by cholesterol depletion with MbCD (7.5 mM
for 1 h prior to HCV infection) as described previously [42] [46].
The effects of MbCD were rescued by reconstituting cholesterol
(150 mg/ml, 1 hr prior to HCV infection). Also, we used
Interferon-a (10 IU/ml for 18 hr prior to and during HCV
infection) [7], or methyl cytidine (1 mM for 3 hr prior to and
during HCV infection) [47] to inhibit HCV replication. All patient
samples obtained, both livers and HCV sera were exempted from
informed consent by the IRB, as all identifiers had been removed
prior to procurement for the study.
Infection of Naı ¨ve Human Hepatocyte Cultures with
Human Hepatocyte Culture-derived HCV
The m.o.i. were for genotype 1: 1 viral particle /25 hepatocytes
for the primary infection, and 33 viral particles/25 hepatocytes for
the secondary infection; for genotype 2: 1.2 viral particle/25
hepatocytes for the primary infection, and 44 viral particles/25
hepatocytes for the secondary infection; and genotype 3: 0.4 viral
particle/25 hepatocytes for the primary infection, and 33 viral
particles/25 hepatocytes for the secondary infection. Naı ¨ve day-5
primary human hepatocytes were cultured with 20 ml of cell layer
lysates (estimated to be comparable to the original inoculums or
approximately 1 viral particle/25 hepatocytes) from the day 10
post-infection primary HCV-infected human hepatocyte cultures
that had 3 media changes prior to harvest. HCV RNA was
determined on primary and secondary infections on day-10 and
day-7, respectively, after Equilibrium Ultracentrifugation of HCV
particles (see below), as described above. In other experiments
naı ¨ve human hepatocytes were cultured in a methionine-free
medium for 24 hr. After this period, hepatocytes were infected for
72-hr as above, but in the presence of 100 mCi [
35S]-methionine
(.1,000Ci/mMol) (MP Biomedicals). HCV E-2 was immunopur-
ified from cell layers, immunoblotted and the E-2 bands were
excised and counted using a Beckman LS 6500 liquid scintillation
counter.
Immunoprecipitation and Immunoblotting
HCV E-2, HCV core, and b-actin were detected by
immunoblotting the immunoprecipitates from hepatocyte lysates
as described [58] following the chemiluminescence protocol
(DuPont) and using purified IgG antibodies as described [59].
Immunoblots were quantified on a Kodak 4000 Imaging Station
and software as described [31].
HCV RNA Determination
Total RNA was isolated from HCV infected primary human
hepatocytes using the TRizol Reagent from Invitrogen (California)
following the manufacturers protocol. DNA digestion was
performed with TURBO DNase from Ambion (Texas) following
the manufacturers protocol. The cDNA synthesis was performed
using AffinityScript RT and Fermentas Rnase Inhibitor from
Stratgene (California), per manufacturers protocol., using
HCVDNAprimer (59-ATGACCTTACCCAAATTGCG-39) or a ran-
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gene specific primer or random 9-mer. PCR was performed using
Qiagen’s (California) HotStar Taq DNA Polymerase. Primers
were: NCR5: 59-CCTCCCGGGAGAGCCATAGT and NCR3:
59-ACAAGGCCTTTCGCGAACCCAA. The amplicon was
,150 bp. PCR conditions were: Cycle Temp time 1 cycle 95u
15 min, 58–60 cycles; 94u 20 sec, 55u 30 sec, 72u 30 sec,1cycle
10u ‘. Gel Analysis was performed on a 2% TBE gel run at 100v
for 15–20 min. An Apex 100 bp-Low DNA Ladder from Genesee
Scientific (California) was used. Results were compared to HCV
infected liver samples run in tandem.
Confocal Microscopy
Fluorescent labels were observed using a triple-channel
fluorescence microscope or a confocal microscope. Fluorochromes
utilized included TOPRO-3 (blue), Alexa 488 (green) and Alexa
594 (red) (Molecular Probes). The percentage of HCV infected
hepatocytes was determined by confocal microscopy using HCV
E-2 (BioDesign), Core(BioDesign), and NS3 (Santa Cruz Biotech.)
specific antibodies [19] [60]. At least 100 cells were analyzed per
experimental point [28]. We analyzed the nuclear morphology by
staining cells with TOPRO-3 (R&D Systems). Two observers
analyzed each immunofluorescent study independently, with an
intra-observer agreement of .90%.
Affinity Column Chromatography
Catch and Release affinity columns and protocol (Upstate) were
used with HCV E-2 (Biodesign), NS3 (Santa Cruz Biotech.), and
NS5a (Santa Cruz Biotech.) specific antibodies with non-
denaturing buffers as specified by the manufacturer. This method
was more efficient and specific in purifying HCV virions than the
standard immunoprecipitation techniques. Negative and positive
control samples were run in parallel.
Equilibrium Ultracentrifugation of HCV particles
The density of HCV in the human hepatocyte culture system
was performed as described by Yi et al [51]. Primary infections
were incubated for 10 days and Secondary infections for 7 days.
Cells were harvested, supernatants were collected and clarified by
low-speed centrifugation, and concentrated ,10-fold using a
Centricon PBHK Centrifugal Plus-20 filter unit with an Ultracel
PL membrane (100-kDa exclusion) (Millipore, Billerica, MA) and
then layered on top of a preformed, continuous 10 to 40%
iodixanol (OptiPrep, Sigma-Aldrich, St. Louis, MO) gradient
prepared in Hanks balanced salt solution (Invitrogen, Carlsbad,
CA). Gradients were centrifuged in a Beckman SW60 rotor
(Beckman Coulter, Fullerton, CA) at 45,000 rpm for 16 h at 4uC,
and nine fractions (500 ml each) were collected from the top of the
tube. The density of each fraction was estimated by weighing a
100-ml aliquot of each fraction.
Interferon PCR Array
The human Interferon and receptor Array that was used was
from SuperArray (Frederick, MD). RNA Isolation was performed
as above using Invitrogen’s Trizol Reagent. DNA Digestionwas
performed as above using Ambion’s TURBO
TM DNase. After a
rigorous DNA digestion, Chloroform Extraction was performed
followed by a Phenol:Chloroforme extraction. cDNA synthesis was
achieved using Strategene’s Protocols and reagents as above.
Random 9-mer 59-NNNNNNNNN-39, Fermentas Rnase Inhibi-
tor and Stratagene’s AffinityScript RT, 0.5–2.0 ug RNA, and
270 ng random 9-mer were used. 20 uL cDNA reaction mixtures
with 91 uL nuclease-free water was used in the RT2 Profiler
TM
PCR Array System following the manufacturer’s protocol. The
array was run on a Bio-Rad iQ5 Multicolor Real-Time PCR
Detection System and data analysis was performed using the excel
spreadsheet provided by SuperArray.
Northern Blot
In order to generate specific probes for a Northern of our
infected culture systems, it was necessary to clone the sequences
from the serum of each of the HCV viral donors. There would be
no probes available that had sufficient specificity for our individual
donors due to the known genetic drift of the HCV virus. Virus
isolation was performed using BioVintage ( California) Opti-Q-1
Virus Isolation kit. RNA Isolation was done using Invitrogen
Trizol Reagent. For cDNA Synthesis we used: HCVcDNAprimer
59-ATGACCTTACCCAAATTGCG, Fermentas Rnase Inhibitor
,AffinityScript RT, with 0.5–2.0 ug RNA, 2 pmol gene specific
primer, 40 U RNase Inhibitor, and 100 mM DTT at 42uC for
60 min. For the PCR, we used Qiagen’s HotStarTaq DNA
Polymerase, 10 uL of diluted (25-fold) cDNA reaction mixture:
(500 uL H20 added to the 20 uL cDNA reaction mixture). To
generate the HCVg1 probe we used HCVsensePrimer5 59-
gCgACACTCCACCATgAATC and HCVantisensePrimer5 59-
TTCCgCAgACCACTATg. The amplicon was 139 bp. The
conditions were; 1cycle 95u 15 min, 60cycles 95u 30 sec, 55u
30 sec, 68u 30 sec, 1cycle 10u ‘. To generate the HCVg3 and
HCVg4 probes we used (RT-PCR antisense#2) 59- CACTCg-
CAAgCACCCTATCA and (RT-PCR sense) 59- TTCAgCCA-
gAAAgCgTCTAg. The expected amplicon was 259 bp. The
conditions used were: 1cycle 95u 15 min, 60cycles 95u 30 sec, 55u
30 sec, 68u 30 sec, and 1cycle 10u ‘. PCR purification was
performed using Qiagen’s QIAquick PCR Purification Kit. The
amplicon was ligated to Promega’s pGEM T-easy vector at a ratio
of Vector : Insert 1 : 2 using a Roche Rapid Ligation kit. The
ligation was transformed into Promega’s JM109 cells andplated
onto LB+Carbenicillin+X-gal+IPTG plates. Plasmids were isolat-
ed using Qiagen’s QIAprep Spin Miniprep Kit. Resulting
plasmids were sequenced by the CFAR Molecular Biology Core
(http://molbiocore.ucsd.edu/). The templates were linearized
with Pst I (NEB), and SpeI (NEB)[ sense strand synthesis], and
Not I (NEB), and Sph I (NEB)[ antisense strand synthesis].
Digests were analyzed on a 1% TAE gel. Linearized plasmids were
treated with Proteinase K (100–200 ug/mL Proteinase K and
0.5% SDS for 30 min at 50uC), and phenol:chloroform extracted.
Probes were generated from the linearized plasmids using
Ambion’s MAXIscript Kit, 500 uM total (for each ATP, GTP,
UTP), 3.125 uM total for CTP, 1 ug DNA template, and Cytidine
59-Triphosphate, ([a-32P], 6000 Ci/mmol, MP BioMedicals).
1 uL Ambion’s TURBO DNase was used to digets the template
DNA. Removal of unincorporated nucleotides was achieved with
NucAway Spin Columns. The Northern Blot was prepared with
Ambion’s NorthernMax –Gly. 30 ug of Total RNA was loaded
into gel with Sigma Aldrich RNA ladder. Gel was run at 5V/
cmand transferred using a Schleicher & Schuell Turboblotter onto
Schleicher & Schuell Nytran N membrane and Crosslinked with
Fisher Brand UV Crosslinker. Hybridization was performed with
1610
6 cpm/mL probe using Ambion’s NorthernMax –Gly
protocol. The hybridized membrane was exposed to BlueDevil
Film from Genesee Scientific. Sigma’s Transcript RNA Markers
(0.28–10 kb) were used.
RT-PCR for GFAP, CD34, CR1, HGF, and CD68
RNA Isolation was performed using Invitrogen Trizol Reagent
as above. Ambion’s TURBO
TM DNase was used for DNA
digestion. Following rigorous DNA digestion and phenol:chloro-
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Protocol and Random 9-mer 59-NNNNNNNNN-39, Fermentas
Rnase Inhibitor, and Stratagene’s AffinityScript RT with 2.0 ug
RNA, and 270 ng random 9-mer. The qRT-PCR Master Mix was
SuperArray’s RT
2 qPCR Master Mixes and the primers were:RT
2
qPCR Primer Assay for Human GFAP: PPH02408E, RT
2 qPCR
Primer Assay for Human CD34: PPH02455E, RT
2 qPCR Primer
Assay for Human CR1: PPH17118A, RT
2 qPCR Primer Assay
for Human HGF: PPH00163B and RT
2 qPCR Primer Assay for
Human CD68: PPH05574E. The protocol was from SuperArray;
RT2 qPCR Primer Assays, Real-Time RT-PCR Gene
Expression Analysis, Part #1016A Version 1.5 6/22/2007, pgs.
13-14.
Human Livers
We obtained anonymous, de-identified liver samples from 4
patients with chronic hepatitis C viral infection and severe liver
fibrosis (Metavir scores of 3 or 4) (53+/217 years) and from 3
control subjects without liver disease (60+/213 years) (NDRI).
Statistical Analysis
Results are expressed as mean (6SD). Either the Student-t or
the Wilcoxon Mann-Whitney tests were used to evaluate the
differences of the means between groups for parametric and non-
parametric populations, respectively, with a P value of ,0.05 as
significant.
Supporting Information
Figure S1 HCV Infection Genotypes 2 and 3 of the Human
Hepatocyte Culture System. A. Day-5, primary human hepato-
cytes infected with HCV genotypes 2 or 3 (inoculums: 28,700 and
44,300 HCV virions, respectively) and control cells were processed
as described in Materials and methods. Scanning confocal laser
microscopy was performed for nucleic acids (TO-PRO-3), HCV
E-2, HCV core and HCV NS-3 as described in Fig 1. Twenty-four
hours infected hepatocytes expressed HCV E-2, core and NS-3
proteins. Control hepatocytes had only background fluorescence
for HCV E-2 and core proteins (upper panels). Co-localization of
HCV E-2 (red) and HCV core (green) is shown in yellow (merge),
while co-localization of nucleic acids (blue), HCV E-2 (red) and
HCV core (green) is shown in white (merge) in HCV-infected
human hepatocyte cultures. Co-localization of HCV NS3 (green)
is shown in yellow (merge) in HCV-infected human hepatocyte
cultures (lower panels). Control hepatocytes received control
human sera. Representative results from triplicate samples of
three independent experiments with human hepatocytes cultures
are shown.
Found at: doi:10.1371/journal.pone.0002660.s001 (1.32 MB TIF)
Figure S2 HCV-Infection with Genotypes 2, 3 and 4 of Normal
Human Hepatocytes is Dependent on HCV E-2. Day-5 primary
human hepatocytes were infected with HCV genotype 2 (42,600
HCV virions), genotype 3 (37,800 HCV virions) and genotype 4
(62,500 HCV virions ) , as described in Materials and methods.
HCV RNA replication was determined at 72 hr after infection.
Human hepatocyte cultures were treated prior to HCV infection
without or with antibodies specific to HCV E-2 as described in
Materials and methods. Antibodies against HCV E-2 decreased
HCV RNA for all genotypes (P,0.05). The control hepatocytes
had the same amount of control human IgG.
Found at: doi:10.1371/journal.pone.0002660.s002 (0.25 MB TIF)
Table S1 Quantitative Changes in Interferon-Related Genes in
the Human Hepatocyte Culture System Infected with HCV
Genotype 1. Day-5 primary human hepatocytes were infected
with HCV genotype 1 (38,100 HCV virions), as described in
Materials and methods. A panel of 83 interferon-related genes was
evaluated by RT-QPCR; 22 of these genes were significantly
altered (P,0.05 for all genes) compared to control uninfected
human hepatocyte cultures . Ten genes were increased ( # 1; #
33; # 48; # 66; # 67; # 68; # 69 ; # 73; # 74; and # 79) , while
twelve genes were decreased ( # 6; # 17; # 25; # 26; # 27; # 29;
# 31; # 32; # 41; # 50; # 51; and # 52).
Found at: doi:10.1371/journal.pone.0002660.s003 (0.12 MB
DOC)
Table S2 The Human Hepatocyte Culture System Produces
HCV Genotypes 2 and 3 with a Density of Infectious Virions.
HCV genotypes 2 and 3 virions were isolated by isopycnic
ultracentrifugation through an iodixanol gradient as described in
Material and methods from the human hepatocyte primary
infection and from the human hepatocyte secondary infection.
The densities below 1.09 g/cm3 consistent with infectious virions,
comprised approximately 82% and 80% for genotype 2, and 85%
and 87% for genotype 3, of the primary infection or the secondary
infection , respectively .
Found at: doi:10.1371/journal.pone.0002660.s004 (0.03 MB
DOC)
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